SELIMETRY—a multicentre I-131 dosimetry trial: a clinical perspective
Jonathan Wadsley(Weston Park Cancer Centre), Sarah Brown(University of Leeds), Kate Newbold(Royal Marsden NHS Foundation Trust), Rebecca Gregory(Barts Health NHS Trust), Andrew Hall(University of Leeds), Yong Du(Royal Marsden Hospital), Laura Moss(Velindre Cancer Centre), Glenn Flux(Royal Marsden NHS Foundation Trust), Louise Flanagan(University of Leeds)
Cited by 32
Related Papers
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
|The Lancet Oncology|2013|728
2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer
|Thyroid|2021|699